<DOC>
	<DOCNO>NCT02017639</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect single 200 mg subcutaneous injection sarilumab pharmacokinetics simvastatin patient rheumatoid arthritis Secondary Objective : To describe safety efficacy ( exploratory ) sarilumab</brief_summary>
	<brief_title>Sarilumab Effect Pharmacokinetics Simvastatin</brief_title>
	<detailed_description>The duration entire study per patient completing Parts A B expect approximately 58 week ( include Screening ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Inclusion criterion : Male female , 18 75 year age , inclusive . Body weight 50.0 120.0 kg , inclusive , male , 40.0 110.0 kg , inclusive , female . Diagnosis RA , accord ACR/European League Rheumatism ( EULAR ) 2010 Rheumatoid Arthritis Classification Criteria ≥ 3 month disease duration , ACR Class IIII functional status , base 1991 revised criterion ( Appendix B , 5 ) . Moderatetoseverely active RA , define : high sensitivity Creactive protein ( hsCRP ) ≥ 6 mg/L Laboratory parameter within normal range ( define screen threshold Investigator site ) , unless Investigator considers abnormality clinically irrelevant RA patient ; however follow lab value must meet : Hemoglobin &gt; 8.5 g/dL White blood cell &gt; 3000/mm3 Neutrophils &gt; 2000/mm3 Platelet count &gt; 150 000 cells/mm3 Exclusion criterion : Prior current significant concomitant illness ( e ) , accord Investigator 's judgment , would adversely affect patient 's participation study . Women childbearing potential protect highlyeffective contraceptive method ( ) birth control ( define inform consent form ) , and/or unwilling unable test pregnancy . Participation clinical research study evaluate investigational drug therapy within 5 halflives 60 day Screening , whichever longer . Patients active TB history incompletely treat TB . History chronic infection active infection . History , current , autoimmune inflammatory systemic localize joint disease ( ) RA . A systemic hypersensitivity reaction , localize injection site reaction , biologic drug . History presence drug alcohol abuse . Prior current interstitial lung disease diagnose high resolution compute tomography and/or lung biopsy consistent finding pulmonary function test corroborate clinical finding . Prior current history malignancy , include lymphoproliferative disease , adequatelytreated carcinoma insitu cervix , nonmetastatic squamous cell basal cell carcinoma skin , within 5 year prior screen visit . Uncontrolled diabetes mellitus , define glycosylated hemoglobin ( HbA1c ) ≥9 % screen visit . Current treatment antiTNF agent biologics . Current treatment RAdirected biologic agent non TNFα antagonist . Any contraindication simvastatin , accord applicable labeling . Current treatment statin within 14 day inclusion . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>